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Abstract
Background: Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2
receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and
prolactinoma through inhibition of hyperprolactinemia and induction of tumor cell apoptosis,
respectively, but the molecular mechanism of bromocriptine induction of pituitary tumor apoptosis
remains unclear. Caveolin-1 is a membrane-anchored protein enriched on caveolae, inverted flask-
shaped invaginations on plasma membranes where signal transduction molecules are concentrated.
Currently, caveolin-1 is thought to be a negative regulator of cellular proliferation and an enhancer
of apoptosis by blocking signal transduction between cell surface membrane receptors and
intracellular signaling protein cascades. Rat pituitary adenoma GH3 cells, which express
endogenous caveolin-1, exhibit increased apoptosis and shrinkage after exposure to
bromocriptine. Hence, the GH3 cell line is an ideal model for studying the molecular action of
bromocriptine on prolactinoma.
Results: The expression of endogenous caveolin-1 in GH3 cells was elevated after bromocriptine
treatment. Transiently expressed mouse recombinant caveolin-1 induced apoptosis in GH3 cells
by enhancing the activity of caspase 8. Significantly, caveolin-1 induction of GH3 cell apoptosis was
sensitized by the administration of bromocriptine. Phosphorylation of caveolin-1 at tyrosine 14 was
enhanced after bromocriptine treatment, suggesting that bromocriptine-induced phosphorylation
of caveolin-1 may contribute to sensitization of apoptosis in GH3 cells exposed to bromocriptine.
Conclusion: Our results reveal that caveolin-1 increases sensitivity for apoptosis induction in
pituitary adenoma GH3 cells and may contribute to tumor shrinkage after clinical bromocriptine
treatment.
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Background
Prolactinomas, prolactin-secreting pituitary adenomas,
are the most frequently found functional pituitary tumors
in humans. The pathology of prolactinomas involves dys-
function of lactotrophic cells in the anterior pituitary
gland which in turn leads to hyperprolactinemia [1]. First
line therapy for prolactinomas includes management
with dopamine agonists. Bromocriptine is commonly
chosen as a therapeutic agent for patients with prolactin-
omas or other pituitary adenomas; bromocriptine binds
to the dopamine D2 receptor on pituitary epithelial cells
to inhibit prolactin secretion [2]. Treatment with bromoc-
riptine causes tumor shrinkage [3]. A rat pituitary prolac-
tinoma cell line, GH3 is commonly used as a cellular
model for studying prolactinoma formation. Long-term
incubation of GH3 with bromocriptine induces cell apop-
tosis [4].
Caveolin-1 is a 21–24 kDa major integral membrane pro-
tein on caveolae, an invaginated structure on cellular
membranes enriched with high numbers of cholesterol,
glycosphingolipid and signaling molecules [5]. Caveolin-
1 has been suggested to negatively regulate many different
signaling molecules located on caveolae via mutual inter-
actions that compartmentalize the signaling molecules
and suppress cell growth [6]. Caveolin-1 is functionally
involved in endocytosis, transcytosis, cholesterol trans-
port, homeostasis, negative regulation of Ras-, NO-, and
G-protein-coupled-receptors, and growth-factor-mediated
protein kinase signaling cascades [7-9].
There is growing evidence that loss of caveolin-1 expres-
sion is associated with tumorigenesis [10-12]. Down-reg-
ulation or absence of caveolin-1 expression has been
found in many human cancers, including primary breast,
prostate, and colon cancers [13-15]. Furthermore, caveo-
lin-1 null mice are more susceptible to carcinogen-
induced tumorigenesis [10], suggesting that caveolin-1
may be a tumor suppressor.
There is accumulating experimental evidence in vivo and
in vitro that caveolin-1 expression sensitizes cells to apop-
totic stimulation. Elevated expression of endogenous
caveolin-1 is associated with induction of apoptosis in
mouse peritoneal macrophages [16]. Ectopic expression
of caveolin-1 in NIH3T3 cells and T24 human bladder car-
cinoma cells sensitizes cells to staurosporine-induced
apoptosis [17]. These data demonstrate that an up-regula-
tion of caveolin-1 may be involved in promoting cell
apoptosis.
In the present study, we investigated the effects of caveo-
lin-1 on pituitary adenoma shrinkage in response to bro-
mocriptine treatment at clinically-relevant concentrations
in GH3 cells. Here we show that caveolin-1 in GH3 cells
was up-regulated after bromocriptine treatment. Our data
show that increased caveolin-1 expression sensitizes pitu-
itary adenoma GH3 cells to apoptosis induced by bro-
mocriptine treatment and clarifies the molecular
mechanism of bromocriptine therapy of pituitary ade-
noma.
Results
Ectopic expression of recombinant caveolin-1 in GH3 cells 
results in apoptotic phenotypes
Caveolin-1 is associated with apoptosis and has been
detected in GH3 cells [18]. As bromocriptine stimulates
GH3 cell shrinkage and apoptosis, we hypothesized that
bromocriptine treatment would induce GH3 cell apopto-
sis via caveolin-1. Semi-quantitative RT-PCR was used to
detect the amount of caveolin-1 mRNA in rat GH3 cells
before and after bromocriptine administration at different
dosages according previous report [4]. Caveolin-1 mRNA
was elevated after 24 hours of bromocriptine treatment in
a dose-dependent manner (Fig. 1A,a). To explore the
function of caveolin-1 in GH3 cells, a pcDNA4-Caveolin-
1 plasmid containing Myc-tagged mouse caveolin-1 under
the control of the CMV promoter was constructed and
successfully transfected into GH3 cells. A predicted 30
kDa recombinant protein was recognized by an anti-cave-
olin-1 antibody (Fig. 1A,b) and by an anti-Myc antibody
(Fig. 1A,c). Twenty-four kDa endogenous caveolin-1
expressed in the A431 cell line, and recognized by an anti-
caveolin-1 antibody, was used as the positive control in
Western blotting (Fig. 1A,b). We next clarified whether the
recombinant caveolin-1 was localized in cells in the same
manner as endogenous caveolin-1. The distribution of
endogenous caveolin-1 in A431 cells was determined by
immunofluorescent staining with an anti-caveolin-1 pol-
yclonal antibody. Exogenous Myc-tagged caveolin-1 dis-
tribution in A431 cells was detected by double
immunofluorescent staining with anti-caveolin-1 and
anti-Myc polyclonal antibodies. Both endogenous and
exogenous caveolin-1 had the same punctate distribution
in the perinuclear region (Fig. 1B,a and 1B,b). We then
transiently expressed the Myc-tagged caveolin-1 in GH3
cells to examine the effect of caveolin-1 on GH3 cells. By
48 hours after caveolin-1 expression in GH3 cells, apopto-
sis-like nuclear condensation was visible upon staining
with Hoechst 33342 (bisbenzimide, Fig. 2E). In the con-
trol experiment, transient expression of enhanced-green
fluorescent protein (EGFP) did not alter nuclear morphol-
ogy (Fig. 2F). These data indicate that transient expression
of Caveolin-1 induces apoptosis in GH3 cells. To test this,
the TUNEL assay, which discriminates apoptosis from
necrosis and from primary DNA strand breaks, was used
to measure DNA fragmentation 48 hours after transfec-
tion [19]. Recombinant caveolin-1-expressing cells
appeared shrunken with positive TUNEL labeling (Fig.
3A,d). In the control experiments, all cells were positivelyCancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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Bromocriptine enhances endogenous caveolin-1 mRNA expression in GH3 cells Figure 1
Bromocriptine enhances endogenous caveolin-1 mRNA expression in GH3 cells. (A) Panel a: Expression of caveo-
lin-1 mRNA was enhanced after bromocriptine treatment. Panel b and c: Cellular proteins were extracted and Western blots 
performed 48 hours after recombinant caveolin-1 was transfected into GH3 cells (lane 2 and 5). Vehicle transfections (lane 1 
and 4) were used as controls. Panel b is an immunoblot using rabbit anti-caveolin-1 antibody and panel c is an immunoblot using 
monoclonal anti-Myc antibody against Myc-tagged caveolin-1. Arrowhead indicates Myc-tagged caveolin-1. Arrow indicates 
endogenous caveolin-1. Protein extracted from A431 cells was used as an immunoblotting positive control. (B) Recombinant 
caveolin-1 expressed in A431 cells has identical perinuclear localization with endogenous caveolin-1. Myc-tagged caveolin-1 was 
transfected into A431 cells (a, c) for 48 hours. Non-transfected A431 cells were used to examine endogenous caveolin-1 local-
ization (b, d). Cells were fixed and immunocytochemically stained with anti-caveolin-1 antibody then visualized by anti-rabbit 
IgG conjugated-FITC secondary antibody to detect exogenous (a) and endogenous (b) caveolin-1. Monoclonal anti-Myc anti-
body combined with anti-mouse IgG conjugated-Texas-Red was used to recognize recombinant caveolin-1 (c). Filamentary 
actin was stained with phalloidin conjugated-Texas-Red to observe cell morphology (d). Scale bar = 20 μm.Cancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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TUNEL labeled after exposure to DNase I (Fig. 3A,f),
whereas no cell was TUNEL labeled after vehicle treatment
(Fig. 3A,h). We quantified the proportion of apoptotic
cells in ectopic caveolin-1 or EGFP-expressing cells by
counting the number of cells exhibiting nuclear conden-
sations per 100 exogenous caveolin-1- or EGFP-expressing
cells, stained with Hoechst 33342. Significant numbers of
caveolin-1 expressing cells exhibited apoptosis after trans-
fection (13% at 24 and 53% at 48 hours), whereas only
2% and 3% of EGFP-expressing cells and 1.6–2% vehicle-
treated cells exhibited apoptosis 24 and 48 hours after
transfection (Fig. 3B). This result revealed that even tran-
sient caveolin-1 expression increased GH3 cell apoptosis.
Caveolin-1 induced apoptosis of GH3 cells involves 
caspase 8
The activation of caspases plays a pivotal role in the exe-
cution of apoptosis by various signaling pathways
[20,21]. To examine the role of caspases in apoptotic GH3
cells after transient caveolin-1 expression (Fig. 4), we sep-
arately treated the ectopic caveolin-1 and DsRed-N1
expressing GH3 cells with a general caspase inhibitor (Z-
VAD-fmk), as well as specific caspase inhibitors, for cas-
pase 3 (Z-DEVE-fmk), caspase 8 (Z-IETD-fmk) or caspase
9 (Z-LEHO-fmk) before determining the number of apop-
totic cells by TUNEL assay. Over-expression of caveolin-1
resulted in 62% of the transiently-transfected cells becom-
ing apoptotic. This effect was inhibited by treating GH3
cells with the general caspase inhibitor Z-VAD-fmk (24%
apoptotic caveolin-1 expressing cells) and with the cas-
pase 8 specific inhibitor, Z-IETD-fmk, (20% apoptosis).
Treatment with caspase 3 or caspase 9 specific inhibitors
did not inhibit caveolin-1 induced apoptosis (apoptosis
decreased by 8 and 13%, respectively; P > 0.05). In nega-
tive control experiments, cells expressing the red fluores-
cent protein, DsRed-N1 had no significant increase in
apoptosis compared to untreated GH3 cells (8% versus
2%, respectively). Treatment of GH3 cells with Z-FA-fmk,
a negative control caspase inhibitor reagent, however, did
not significantly inhibit caveolin-1 induced apoptosis
(59% of cell apoptosis), indicating that activation of cas-
pases plays a role in caveolin-1 induced GH3 cell apopto-
sis, at least in part through caspase 8 signaling.
Bromocriptine sensitizes the caveolin-1 induced apoptosis 
in GH3 cells
Bromocriptine induces activation of p38 MAP kinase in
GH3 cells [12]. Activation of the p38 MAP kinase signal-
ing pathway in NIH3T3 cells causes phosphorylation of
caveolin-1 on Tyr14 [22]. We examined if there was any
relationship between bromocriptine and caveolin-1 that
affected GH3 cell apoptosis. GH3 cells were allowed to
transiently express caveolin-1 for 24 hours, then 30 μM
bromocriptine was added for another 12 hours. The pro-
portion of apoptotic cells was determined by estimating
the number of cells containing condensed nuclear DNA.
After 12 hours of bromocriptine treatment, the number of
apoptotic cells was 38% of the total caveolin-1 expressing
cell population compared to 24% without bromocriptine
(Fig. 5A). Only 14% and 6% of the total cell population
underwent apoptosis when cells were treated with bro-
mocriptine or vehicle for 12 hours (Fig. 5A). The data
indicate that there is an interaction between caveolin-1
and bromocriptine in the induction of GH3 apoptosis.
Overexpression of caveolin-1 induces nuclear condensation  in GH3 cells Figure 2
Overexpression of caveolin-1 induces nuclear condensation 
in GH3 cells. GH3 cells were transfected with either 
pcDNA4-caveolin-1 (A, C and E) or pcDNA4-EGFP (B, D 
and F). Immunocytochemical staining was carried out 48 
hours after transfection. Phalloidin conjugated-Texas-Red (A 
and B) and Hoechst 33342 (E and F) dyes were used to stain 
F-actin and nuclei respectively. Cells expressing caveolin-1 
(arrowhead) were visualized by anti-rabbit IgG conjugated-
FITC secondary antibody (C). Caveolin-1 overexpressing 
cells exhibit nuclear condensation (E), while normal nuclei 
(arrow) were detected in cells over-expressing EGFP (F). 
Scale bar = 20 μm.Cancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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Over-expression of caveolin-1 induces apoptosis of GH3 cells Figure 3
Over-expression of caveolin-1 induces apoptosis of GH3 cells. (A) GH3 cells were transfected with pcDNA4-Caveolin-1 for 
48 hours then subjected to TUNEL assays. Cells transiently expressing exogenous caveolin-1 (indicated by arrowheads) 
showed shrunken morphologies (a and b) and nuclear fragmentation when stained with Hoechst 33342 dye (c) and were posi-
tively fluorescence-labeled by TUNEL assay (d). Cells directly treated with DNase I (e, f) or vehicle (g, h) were TUNEL positive 
(f) or negative (h), respectively. Nuclei stained with Hoechst 33342 dye are shown in c, e and g. (B) Caveolin-1 elicited apopto-
sis of GH3 cells. GH3 cells were transfected with pcDNA4-caveolin-1, pcDNA4-EGFP or vehicle (null treatment) and sub-
jected to immunocytochemical staining 24 and 48 hours after transfection. Three hundred cells were randomly chosen and 
counted in each experiment (vehicle, caveolin-1 or EGFP) to determine the percentage with fragmented nuclei after Hoechst 
33342 dye labeling. Apoptotic cells were measured by fluorescence labeling and data were expressed as mean ± standard devi-
ation from n = 3 independent experiments (angular transformed for analysis, back-transformed for presentation). The standard 
deviations are too small to observe in the 48 hours data. **P < 0.01 and *P < 0.05 versus EGFP or vehicle experiment.Cancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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Bromocriptine enhances phosphorylation of caveolin-1 
Tyr14
Tyrosine14 phosphorylation of caveolin-1 was found to be
associated with apoptosis in the human promyelocytic
leukemia cell line HL-60 after etoposide induction [23],
indicating phosphorylation of caveolin-1 tyrosine may
play a role in apoptosis. To explore whether bromocrip-
tine could induce caveolin-1 phosphorylation, GH3 cells
were transfected with pcDNA4-caveolin-1 for 24 hours,
then exposed to bromocriptine as indicated in figure 5B.
Total proteins were extracted, separated using SDS-PAGE
and examined by Western blotting using an antibody spe-
cific for caveolin-1 phosphorylated at Tyr14. After 12 hours
of bromocriptine treatment the amount of caveolin-1
phosphorylation was 3.75 times higher than with vehicle
(ethanol) treatment (Fig. 5B). Cellular protein from
H2O2-exposed NIH3T3 cells was used as a positive control
for phosphorylated caveolin-1. These data demonstrated
that bromocriptine enhanced phosphorylation of caveo-
lin-1 in GH3 cells.
Discussion
In the present study, we demonstrated GH3 cells overex-
pressing caveolin-1 underwent apoptosis. Caveolin-1 has
Caveolin-1 induces GH3 apoptosis via caspase 8 activity Figure 4
Caveolin-1 induces GH3 apoptosis via caspase 8 activity. 
Caspase inhibitors (50 μM) were added to either pcDNA4-
Caveolin-1 or pcDNA4-DsRed-N1 (negative control) trans-
fected GH3 cells and the proportion of apoptotic cells quan-
tified 48 hours after transfection by immunocytochemical and 
TUNEL assays. Data were expressed as mean ± standard 
deviation from 3 independent experiments (angular trans-
formed for analysis, back-transformed for presentation). 
Abbreviations on the x-axis: General caspase inhibitor (Z-
VAD-fmk); a negative control inhibitor (Z-FA-fmk); specific 
caspase inhibitors for caspase 3 (Z-DEVE-fmk), caspase 8 (Z-
IETD-fmk) or caspase 9 (Z-LEHO-fmk).
A combination of bromocriptine treatment and overexpres- sion of Caveolin-1 enhances apoptosis of GH3 cells Figure 5
A combination of bromocriptine treatment and overexpres-
sion of Caveolin-1 enhances apoptosis of GH3 cells. (A) GH3 
cells were transfected with caveolin-1 for 24 hours and then 
treated with or without 30 μM bromocriptine for another 12 
hours. Non-transfected cells were treated for 12 hours with 
ethanol alone (vehicle) or bromocriptine. Cells expressing 
exogenous Caveolin-1 were immunostained with anti-Myc 
antibody and then detected with anti-mouse IgG Texas Red-
conjugated secondary antibody. Three hundred Caveolin-1 
expressing cells were counted in each experiment and apop-
totic cells were determined by nuclear fragmentation after 
staining with Hoechst 33342 dye. Data were expressed as 
mean ± standard deviation from 3 independent experiments 
(angular transformed for analysis, back-transformed for pres-
entation). (B) Phosphorylation of Tyr14 was enhanced when 
GH3 cells were exposed to bromocriptine. Cells were 
administered 30 μM bromocriptine as indicated, 24 hours 
after pcDNA4-caveolin-1 transfection. Cellular protein was 
extracted and separated on 12% SDS-PAGE then subjected 
to Western blotting. Anti-caveolin-1 or anti-phosphorylated 
caveolin-1 (Tyr14) specific antibodies were used to measure 
total and phosphorylated caveolin-1 respectively. Cellular 
protein extracts from NIH3T3 cells exposed to H2O2 were 
used as a positive control to detect phosphorylated caveolin-
1. Dash (-) indicates vehicle treatment. The arrowhead 
points to endogenous caveolin-1 and the arrow marks 
recombinant caveolin-1. Abbreviation: Br, bromocriptine. *P 
< 0.05 versus experiment for caveolin-1 transient expression 
only or bromocriptine treatment only.Cancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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previously been reported to be associated with enhance-
ment of apoptotic sensitivity. For example, NIH3T3 cells
treated with anti-sense caveolin-1 were resistant to stau-
rosporine-induced apoptosis, and T24 bladder carcinoma
cells were sensitized to caspase 3 activation when stably
expressing recombinant caveolin-1 [17]. Large increases
in caveolin-1 expression have also been observed in apop-
totic-agent-treated mouse peritoneal macrophages [16].
In addition, retrovirus insertion-mediated random muta-
genesis applied to L292 cells revealed caveolin-1 is neces-
sary for apoptosis induced by TNF-α [24]. These reports
highlight a growing body of evidence indicating that up-
regulated expression of caveolin-1 is associated with cell
apoptosis. This study has now shown, for the first time,
that caveolin-1 itself induces apoptosis of rat anterior
pituitary epithelial cells of the GH3 cell line.
We have shown that caveolin-1 mRNA expression was fur-
ther enhanced in GH3 cells after 24 hours of bromocrip-
tine stimulation. It is known that with bromocriptine
stimulation of GH3 cells leads to accumulation of wild
type p53 [25]. There are two consensus half sites (-292 to
-283 bp and -273 and -264 bp) in the caveolin-1 promoter
that are predicted to be wild type p53 binding sites. Previ-
ous experiments have also shown that transfection of wild
type p53 into human skin fibroblasts is accompanied by a
six-fold increase in caveolin-1 promoter transcription
activity [26]. Therefore, and supported by evidence from
this study, we speculate that bromocriptine enhances
caveolin-1 expression via an increase in wild-type p53
expression in GH3 cells.
Caspases play critical roles in the initiation and execution
of the apoptotic process [20]. We found that, at least in
part, caspase 8 might be required for caveolin-1 induction
of GH3 cell apoptosis. In contrast, up-regulation of cave-
olin-1 sensitizes NIH3T3 fibroblasts and T24 bladder car-
cinoma epithelial cells to apoptotic stimuli via increased
activation of caspase 3 [17]. Caveolin-1 up-regulation is
also associated with simvastatin-induced apoptosis of thi-
oglycollate-elicited mouse peritoneal macrophages; this
effect was independent of caspase activity, because the
general caspase inhibitor Z-VAD-Fmk failed to block cell
death [16]. Together these results indicate caveolin-1
mediates cellular apoptosis through variant signaling
pathways in different cell types.
Treatment of lymphocytes and NIH3T3 cells with H2O2 or
UV light induces phosphorylation of caveolin-1 Tyr14
[27,17]. In addition, caveolin-1 phosphorylated at Tyr14
specifically co-localizes with paxillin at focal adhesion
complexes after epidermal growth factor, insulin or H2O2
treatment, suggesting phosphorylation of caveolin-1 is
associated with cellular morphological changes and
shrinkage when cells adapt to external cellular stresses
[22,27,28]. In addition, etoposide, a therapeutic agent for
leukemia, in inducing tumor cell apoptosis, increases
phosphorylation of caveolin-1 Tyr14 in HL-60 cells [23].
We demonstrated that phosphorylation of caveolin-1
Tyr14 was increased after bromocriptine treatment and this
accelerated GH3 cells apoptosis, indicating phosphoryla-
tion of caveolin-1 Tyr14 may be important for bromocrip-
tine mediation of cellular apoptosis or morphological
changes in cells encountering apoptotic stress.
Conclusion
In summary, the present results demonstrate that caveo-
lin-1 expression is induced after bromocriptine treatment
in rat pituitary adenoma cells. Moreover, exogenous over-
expression of caveolin-1 increases apoptosis of pituitary
adenoma cells and enhances bromocriptine-induced cell
apoptosis. Interestingly, caveolin-1 was phosphorylated at
Tyr14 when GH3 cells responded to bromocriptine treat-
ment. Phosphorylation of caveolin-1 Tyr14 is predicted to
be associated with cellular apoptosis. These data suggest
that bromocriptine-induced pituitary adenoma cell apop-
tosis may result from enhanced expression and activation
of caveolin-1 via increased caveolin-1 phosphorylation.
Our result explains the therapeutic effect of bromocriptine
in curing pituitary adenoma.
Materials and methods
Materials and reagents
Dulbecco's modified Eagle medium, penicillin, strepto-
mycin, L-glutamine, fetal bovine serum and horse serum
were purchased from Life Technologies (Gaithersburg,
MD). Rabbit anti-caveolin-1 and rabbit anti-phosphor-
ylated caveolin-1 (Tyr14) antibody were bought from
Chemicon Internal Inc. (Temecula, CA). Mouse anti-c-
Myc-antibody (9E10) was obtained from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA). Texas-Red and FITC
conjugated secondary antibodies and normal goat serum
were purchased from Jackson ImmunoResearch Laborato-
ries (West Grove, PA).
Plasmid construction and semi-quantitated RT-PCR
Total RNA was extracted from adult C57Bl/6 mouse brain
with TRIzol reagent (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions. Caveolin-1 cDNA was
amplified from total RNA by RT-PCR and was subcloned
into pGEM T-easy vector by TA cloning (Promega, Madi-
son, WI). The paired primer sequences used for RT-PCR
were as follows: forward primer, 5'-CTCGAGATGTCT-
GGGGGCAAATACGTG-3'; reverse primer, 5'-TCTAGA-
TATCTCTTTCTGCGTGCTGATGCG-3'. The DNA
sequence of caveolin-1 was confirmed by auto-sequencing
using an ABI 3730 autosequenser. Caveolin-1 in the
pGEM T-easy vector was digested with Xho I and Xba I
restriction enzymes and then subcloned into pcDNA4
(Invitrogen, Carlsbad, CA) mammalian expression vector;Cancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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this plasmid was termed pcDNA4-caveolin-1. pcDNA4-
EGFP was cloned as follows: the clone pEGFP-N1 plasmid
containing enhanced green fluorescent protein (EGFP),
obtained from Clontech (Palo Alto, CA), was digested
with Pst I and Not I restriction enzymes, then subcloned
into pcDNA4 vector; this plasmid was designated
pcDNA4-EGFP. pDsRed-N1 containing red fluorescent
protein was purchased from Clontech Laboratories. For
quantifying the level of caveolin-1 cDNA expressed in
GH3 cells modulated after bromocriptine treatment, the
cells were treated with either bromocriptine (Sigma) at
different concentrations of 5, 10, 20 μM or with vehicle
for 24 hours, when total RNA was extracted and the tran-
scripts quantified by RT-PCR, as described above.
Cell culture
The rat GH3 pituitary adenoma and human A431 epithe-
lial cell lines were obtained from the American Type Cell
Collection. The GH3 cells were propagated in F12K nutri-
ent mix medium (Invitrogen, Carlsbad, CA) supple-
mented with 2.5% fetal bovine serum, 15% horse serum,
2 mM L-glutamine, 100 units/ml penicillin, and 100
units/ml streptomycin. The A431 cells were maintained in
DMEM medium containing 10% fetal bovine serum, 2
mM L-glutamine, 100 units/ml penicillin, and 100 units/
ml streptomycin.
Transfections
Transfection of GH3 and A431 cells was performed using
Lipofectamine Plus™ reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's protocol. Briefly, the day
before transfection, 6 × 105 cells were plated on a 6-well
cell culture grade Petri dish. One μg DNA and 6 μl Plus™
reagent were diluted into 100 μl serum-free medium and
4  μl lipofectamine was added to 100 μl serum-free
medium; these two pre-complexes were then mixed and
incubated for 15 min at room temperature. The DNA-
Plus™-lipofectamine reagent complex was added to each
well containing GH3 or A431 cells in fresh serum-free
medium. Cells were incubated at 37°C in 5% CO2 in air
for 3 hours, then the old medium was replaced with fresh
complete medium after incubation. The times after trans-
fection for immunocytochemical staining or TUNEL (ter-
minal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling) analyses are indicated in the results.
Immunocytochemistry
For the analysis of Myc-tagged caveolin-1 expression in
GH3 cells, cells were briefly washed with PBS and fixed
with 4% paraformaldehyde in PBS for 15 min at room
temperature. Cells were permeabilized by incubating with
PBS containing 0.5% Triton X-100 for 10 min. The perme-
abilized cells were immersed in blocking solution con-
taining 10% normal goat serum in PBS for 1 hour. The
cells were then incubated over night at 4°C with either
anti-caveolin-1 (diluted 1:100 in PBS) or Myc (diluted
1:100 in PBS) primary antibody. After three washes with
PBS, cells were incubated with the secondary antibody
(anti-mouse IgG conjugated with FITC, diluted 1:300 in
PBS; anti-rabbit IgG conjugated with Texas-Red or FITC,
diluted 1:300 in PBS) for 2 hours at room temperature.
Slides were mounted with Mowiol 4–88 (Calbiochem, La
Jolla, CA) and visualized by confocal laser scanning
microscopy (Ziess, LSM510) before being digitally photo-
graphed.
TUNEL assay
The TUNEL assays were conducted as previously described
[2] with some modifications. Briefly, DNase I-treated
GH3 cells or cells ectopically expressing caveolin-1 were
washed twice with PBS and fixed with 4% paraformalde-
hyde in PBS, pH7.4, for 10 min at room temperature.
Cells were permeabilized with 0.1% Triton X-100 in 0.1%
sodium citrate for 2 min on ice. Cell ectopically expressing
caveolin-1 were labeled with monoclonal anti-Myc anti-
body, then visualized by Texas-Red conjugated anti-
mouse IgG antibody. Cells were TUNEL labeled using the
In situ Cell Death Detection Kit (Roche, Alcaloid, Man-
nheim, Germany) according to the manufacturer's
instruction.
Caspase inhibitor treatment and quantification of cell 
apoptosis
Treatment with caspase inhibitors and quantification of
cell apoptosis were conducted as follows: GH3 cells were
seeded in a 24 well dish one day before transfection. Cells
were transfected with pcDNA4-caveolin-1 or pDsRed-N1
by Lipofectamine Plus™ reagent. Transfected cells were
treated with caspase inhibitors at 50 mM final concentra-
tion for 48 hours, then immunocytochemical and TUNEL
assays were used to quantify apoptotic cells. Anti-c-Myc
monoclonal antibody was used as the first antibody to
recognize caveolin-1 expressing cells, followed by Texas
Red-conjugated anti-mouse IgG. Cells expressing DsRed-
N1 were directly detected by fluorescent microscopy. The
caspase inhibitors Z-VAD-fmk, Z-DEVE-fmk, Z-IETD-fmk,
and Z-LEHO-fmk, and the negative control Z-FA-fmk were
purchased from Calbiochem Inc. One hundred Myc-
tagged and DsRed-N1 expressing cells were examined in
each experiment for positive TUNEL labeling. Each exper-
iment was repeated three times. Data were analyzed using
the GLM procedure of SAS (v9.1) and significant differ-
ences between means were determined by a Duncan's
New Multiple Range Test (P < .05).
Western immunoblotting
For detecting caveolin-1 and phosphorylated caveolin-1
protein expression in GH3 cells, cellular proteins were
extracted with RIPA buffer (50 mM Tris-HCl, pH 7.0, 1%
NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mMCancer Cell International 2007, 7:1 http://www.cancerci.com/content/7/1/1
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PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptine, 1 μg/ml
peptasin A, 1 mM Na3VO4, 1 mM NaF, 10 mM Na4P2O7)
36 hours after pcDNA4-caveolin-1 transfection. Cell
extracts were then centrifuged at 12000 rpm at 4°C for 10
min, and the supernatants collected. Protein samples were
quantified by the Bio-Rad protein assay kit (cat. no. #500-
0006; Bio-Rad, Inc., Hercules, CA). Each 10 μg sample was
denatured for 5 min at 95°C in Laemmli sample buffer
(2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris HCl,
pH 6.8, 0.01% bromophenol blue). The proteins were
then separated by 12% SDS-PAGE and transferred to
PVDF membranes. Blots were washed with TBST buffer
(120 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween
20) then placed in TBST buffer supplemented with 5%
skimmed milk powder for blocking non-specific interac-
tions for 1 hour at room temperature. Blots were then
incubated with rabbit anti-caveolin-1 antibody (1:1000 in
TBST), mouse anti-Myc antibody (1:3000 in TBST) or
anti-phosphorylated caveolin-1 (Tyr14) polyclonal anti-
body (1:1000 in TBST) overnight at 4°C. After washing
the blots with TBST, membranes were incubated with
horse-radish peroxidase-conjugated secondary antibodies
(1:3000, Amersham Biosciences, Arlington Heights, IL)
for 2 hours and washed again as described previously.
Membrane-bound secondary antibodies were detected
using the ECL procedure developed by Amersham Bio-
sciences. To ensure equal protein loading membranes
were rehybridized with a mouse anti-actin antibody
(1:3000, Chemicon, Inc., Temecula, CA) and developed
using X-ray film (Kodak).
Statistical analysis
Bar charts of the proportion of apoptotic cells of each
treatment group were drawn with the sample mean plus
and minus one standard deviation from three independ-
ent experiments. The angular transformation of observed
proportion data were used for statistical analysis. Analysis
of variance of the group factor in blocks (treating each
experiment as a block) and Tukey's Studentized range test
for group means were performed with SAS v9.1 statistical
analysis package (SAS Institute Inc., Cary, North Caro-
lina).
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